KDR and renal cell carcinoma: When antiangiogenic VEGFR monotherapy was the standard of care, the 5-year survival rate for patients with advanced RCC was 12%.13,14 The extent to which nivolumab-ipilimumab and pembrolizumab-axitinib will improve outcomes remains to be determined.